Special Issue

Hepatocellular Carcinoma: Diagnosis and Management

Message from the Guest Editor

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for ~90% of cases, and is the third leading cause of cancer-related deaths globally. While it has traditionally been diagnosed in its late stages, improved surveillance in patients with cirrhosis and advances in imaging have enabled earlier detection and curative treatment options. Major risk factors include chronic infection with hepatitis B and C viruses, as well as non-alcoholic steatohepatitis (NASH), which is increasingly common in the West and presents a distinct molecular pathogenesis. About 25% of HCCs carry potentially actionable mutations, though their clinical utility remains under investigation. Ultrasound is recommended for the surveillance and follow-up of nodules ≤1 cm. while contrast-enhanced CT or MRI is preferred for nodules >1 cm. Biopsies may be required for atypical lesions but are limited by sampling errors. Subcentimeter lesions should be monitored with repeat imaging and alpha-fetoprotein (AFP) testing every 3-6 months.

Guest Editor

Dr. Po-Ming Chen

- 1. Research Assistant Center, Show Chwan Memorial Hospital, Changhua 500, Taiwan
- 2. Department of Nursing, Central Taiwan University of Science and Technology, Taichung 406, Taiwan

Deadline for manuscript submissions

30 November 2025



Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



mdpi.com/si/237725

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

mdpi.com/journal/diagnostics





Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

